Finanzen von ESSA Pharma Inc (EPIX)EPIXESSA Pharma Inc

Evaluating the bottom line, ESSA Pharma Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -21.25%, provide a clear picture of how effectively EPIX converts its operational activities into shareholder value.

In the context of the broader market, EPIX competes directly with industry leaders such as VYNE and XBIO. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, EPIX's gross margin of N/A stands against VYNE's 100.00% and XBIO's N/A. Such benchmarking helps identify whether ESSA Pharma Inc is trading at a premium or discount relative to its financial performance.